PubRank

Steven Warach

Author PubWeight™ 136.16‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 2007 8.68
2 Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003 7.75
3 Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009 6.02
4 MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 2012 5.91
5 Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004 4.82
6 The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2004 4.39
7 Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2008 3.98
8 DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol 2011 3.18
9 Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006 3.03
10 Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association. Stroke 2009 2.55
11 Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004 2.54
12 Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 2013 2.50
13 Diagnostic and prognostic value of early MR Imaging vessel signs in hyperacute stroke patients imaged <3 hours and treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol 2005 2.28
14 A 62-year-old man with fluctuating neurological deficits and skin lesions. JAMA Neurol 2013 1.99
15 Establishing final infarct volume: stroke lesion evolution past 30 days is insignificant. Stroke 2008 1.94
16 Standardizing the structure of stroke clinical and epidemiologic research data: the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) project. Stroke 2012 1.91
17 Intra- and interrater reliability of ischemic lesion volume measurements on diffusion-weighted, mean transit time and fluid-attenuated inversion recovery MRI. Stroke 2006 1.77
18 Association of ischemic lesion patterns on early diffusion-weighted imaging with TOAST stroke subtypes. Arch Neurol 2003 1.77
19 Acute stroke imaging research roadmap. Stroke 2008 1.66
20 Validation of an acute ischemic stroke model: does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome? Stroke 2007 1.65
21 Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. Stroke 2003 1.62
22 Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2009 1.56
23 CT-NIHSS mismatch does not correlate with MRI diffusion-perfusion mismatch. Stroke 2007 1.55
24 Acute ischemic cerebrovascular syndrome: diagnostic criteria. Stroke 2003 1.49
25 Significance of early CT signs in acute stroke. A CT scan-diffusion MRI study. Cerebrovasc Dis 2002 1.48
26 Multivoxel MR spectroscopy in acute ischemic stroke: comparison to the stroke protocol MRI. Stroke 2012 1.41
27 Acute stroke imaging research roadmap. AJNR Am J Neuroradiol 2008 1.41
28 Acute stroke patients are being underfed: a nitrogen balance study. Neurocrit Care 2004 1.40
29 Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol 2004 1.40
30 Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 2008 1.37
31 MRI screening before standard tissue plasminogen activator therapy is feasible and safe. Stroke 2005 1.35
32 The Virtual International Stroke Trials Archive. Stroke 2007 1.34
33 Negative diffusion-weighted imaging after intravenous tissue-type plasminogen activator is rare and unlikely to indicate averted infarction. Stroke 2013 1.33
34 Trial design and reporting standards for intraarterial cerebral thrombolysis for acute ischemic stroke. J Vasc Interv Radiol 2003 1.27
35 Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 2002 1.24
36 Induced hypertension improves cerebral blood flow in acute ischemic stroke. Neurology 2005 1.18
37 Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke 2007 1.17
38 Whole-brain arterial spin labeling perfusion MRI in patients with acute stroke. Stroke 2012 1.14
39 Verification of enhancement of the CSF space, not parenchyma, in acute stroke patients with early blood-brain barrier disruption. J Cereb Blood Flow Metab 2007 1.13
40 Accuracy and reliability assessment of CT and MR perfusion analysis software using a digital phantom. Radiology 2012 1.11
41 Development and validation of a simple conversion model for comparison of intracerebral hemorrhage volumes measured on CT and gradient recalled echo MRI. Stroke 2008 1.10
42 Imaging of acute stroke. Nat Rev Neurol 2010 1.09
43 Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke 2013 1.08
44 Early ischemic lesion recurrence within a week after acute ischemic stroke. Ann Neurol 2003 1.07
45 Cerebral spinal fluid contamination of the measurement of the apparent diffusion coefficient of water in acute stroke. Magn Reson Med 2002 1.04
46 Quantitative measurements of relative fluid-attenuated inversion recovery (FLAIR) signal intensities in acute stroke for the prediction of time from symptom onset. J Cereb Blood Flow Metab 2012 1.03
47 Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses. Int J Stroke 2012 1.02
48 Spectral localization by imaging using multielement receiver coils. Magn Reson Med 2011 1.02
49 Stromal-derived factor-1[alpha] correlates with circulating endothelial progenitor cells and with acute lesion volume in stroke patients. Stroke 2011 1.01
50 Multiple cerebral microbleeds: MRI marker of a diffuse hemorrhage-prone state. J Neuroimaging 2004 1.00
51 Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 2012 0.97
52 Interleukin-6 174G/C polymorphism and ischemic stroke: a systematic review. Stroke 2007 0.97
53 Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. Stroke 2012 0.97
54 Hypertension-induced vascular remodeling contributes to reduced cerebral perfusion and the development of spontaneous stroke in aged SHRSP rats. J Cereb Blood Flow Metab 2009 0.96
55 Therapeutic time window of thrombolytic therapy following stroke. Curr Atheroscler Rep 2004 0.95
56 Feridex preloading permits tracking of CNS-resident macrophages after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 2009 0.95
57 Predictors of acute stroke mimics in 8187 patients referred to a stroke service. J Stroke Cerebrovasc Dis 2013 0.95
58 Multi-center prediction of hemorrhagic transformation in acute ischemic stroke using permeability imaging features. Magn Reson Imaging 2013 0.94
59 Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. Arch Neurol 2006 0.94
60 Rising statin use and effect on ischemic stroke outcome. BMC Med 2004 0.93
61 Reperfusion-associated hemorrhagic transformation in SHR rats: evidence of symptomatic parenchymal hematoma. Stroke 2008 0.93
62 Reperfusion half-life: a novel pharmacodynamic measure of thrombolytic activity. Stroke 2008 0.93
63 Measurement of glutathione in normal volunteers and stroke patients at 3T using J-difference spectroscopy with minimized subtraction errors. J Magn Reson Imaging 2009 0.92
64 Lesion volume change after treatment with tissue plasminogen activator can discriminate clinical responders from nonresponders. Stroke 2007 0.92
65 Patterns of perfusion-weighted imaging in patients with carotid artery occlusive disease. Arch Neurol 2003 0.91
66 The redefinition of TIA: the uses and limitations of DWI in acute ischemic cerebrovascular syndromes. Neurology 2004 0.90
67 Pseudocontinuous arterial spin labeling quantifies relative cerebral blood flow in acute stroke. Stroke 2012 0.89
68 Telephone assessment of stroke outcome is reliable. Stroke 2005 0.89
69 Increased plasma and tissue MMP levels are associated with BCSFB and BBB disruption evident on post-contrast FLAIR after experimental stroke. J Cereb Blood Flow Metab 2010 0.88
70 Update on stroke. Curr Opin Neurol 2004 0.87
71 Thrombolysis in stroke beyond three hours: Targeting patients with diffusion and perfusion MRI. Ann Neurol 2002 0.87
72 Myocardial injury in acute stroke: a troponin I study. Neurocrit Care 2004 0.85
73 A pragmatic approach using magnetic resonance imaging to treat ischemic strokes of unknown onset time in a thrombolytic trial. Stroke 2012 0.85
74 Circulating CD133+CD34+ progenitor cells inversely correlate with soluble ICAM-1 in early ischemic stroke patients. J Transl Med 2011 0.84
75 Assessing reperfusion with whole-brain arterial spin labeling: a noninvasive alternative to gadolinium. Stroke 2014 0.82
76 The association between neurological deficit in acute ischemic stroke and mean transit time: comparison of four different perfusion MRI algorithms. Neuroradiology 2005 0.82
77 New pathways for evaluating potential acute stroke therapies. Int J Stroke 2006 0.82
78 Stroke imaging research road map. Neuroimaging Clin N Am 2011 0.82
79 Visual perfusion-diffusion mismatch is equivalent to quantitative mismatch. Stroke 2011 0.81
80 Editorial comment--Is there a perihematomal ischemic penumbra? More questions and an overlooked clue. Stroke 2003 0.81
81 Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke 2012 0.81
82 Reversal of perfusion and diffusion abnormalities after intravenous thrombolysis for a lacunar infarction. J Neuroimaging 2003 0.81
83 New brain infarcts on magnetic resonance imaging after coronary artery bypass graft surgery: lesion patterns, mechanism, and predictors. Ann Neurol 2014 0.80
84 More accurate identification of reversible ischemic injury in human stroke by cerebrospinal fluid suppressed diffusion-weighted imaging. Stroke 2004 0.79
85 Imaging. Stroke 2005 0.77
86 Optimizing stroke clinical trial design: estimating the proportion of eligible patients. Stroke 2010 0.75
87 Mismatch and defuse: harvesting the riches of multicenter neuroimaging-based stroke studies. Stroke 2007 0.75
88 Pilot results of in vivo brain glutathione measurements in stroke patients. J Cereb Blood Flow Metab 2012 0.75